NASDAQ:LRMR

Larimar Therapeutics Q3 2026 Earnings Results & Report

Larimar Therapeutics logo
$3.14 -0.08 (-2.48%)
Closing price 04:00 PM Eastern
Extended Trading
$3.09 -0.05 (-1.46%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Larimar Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.29 versus the -$0.3514 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:30 AM ET

Larimar Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.3514
Beat/Miss
Beat by +$0.0614
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Larimar Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Larimar Therapeutics Q3 2026 Earnings FAQ

Larimar Therapeutics (NASDAQ:LRMR) reported earnings of -$0.29 per share for Q3 2026, beating the consensus estimate of -$0.3514. The report was announced on Monday, November 16, 2026.

Larimar Therapeutics Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Larimar Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email.

About Larimar Therapeutics

Larimar Therapeutics (NASDAQ:LRMR) is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria.

Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Larimar is advancing nomlabofusp toward potential FDA approval. In June 2026, the company submitted the first module of its rolling Biologics License Application (BLA), seeking accelerated approval, with the remaining modules expected to be submitted in the second half of 2026. Larimar also plans to explore additional applications for its protein-delivery technology. Its shares trade on the Nasdaq under the symbol LRMR.

View Larimar Therapeutics Profile